Citigroup
RUBY

Citigroup’s Rubius Therapeutics, Inc RUBY Stock Holding History

Citigroup’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,342
Closed -$231 – 6036
2022
Q4 		$231 Buy
1,342
+56
+4% +$15 ﹤0.01% 5588
2022
Q3 		$1K Sell
1,286
-692
-35% -$519 ﹤0.01% 5749
2022
Q2 		$2K Sell
1,978
-30,202
-94% -$50.7K ﹤0.01% 5957
2022
Q1 		$177K Sell
32,180
-105,171
-77% -$668K ﹤0.01% 4136
2021
Q4 		$1.33M Buy
137,351
+42,400
+45% +$588K ﹤0.01% 2970
2021
Q3 		$1.7M Sell
94,951
-90,829
-49% -$1.98M ﹤0.01% 2670
2021
Q2 		$4.54M Buy
185,780
+179,677
+2,944% +$4.49M ﹤0.01% 1978
2021
Q1 		$162K Sell
6,103
-4,850
-44% -$70.8K ﹤0.01% 4122
2020
Q4 		$83K Buy
10,953
+3,278
+43% +$19.5K ﹤0.01% 5692
2020
Q3 		$38K Sell
7,675
-9,276
-55% -$49.1K ﹤0.01% 5769
2020
Q2 		$101K Buy
16,951
+739
+5% +$4.36K ﹤0.01% 5570
2020
Q1 		$72K Buy
16,212
+1,637
+11% +$12.2K ﹤0.01% 5649
2019
Q4 		$138K Buy
14,575
+10,747
+281% +$104K ﹤0.01% 5481
2019
Q3 		$30K Sell
3,828
-7,787
-67% -$90.7K ﹤0.01% 6481
2019
Q2 		$182K Buy
11,615
+1,326
+13% +$21.4K ﹤0.01% 5346
2019
Q1 		$186K Buy
+10,289
New +$158K ﹤0.01% 5183
2018
Q4 		– Sell
-3,400
Closed -$82K – 7886
2018
Q3 		$82K Buy
+3,400
New +$77.7K ﹤0.01% 6088

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Citigroup's RUBY Position: Q1 2023 in Review

Citigroup sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 1,342 shares — an estimated $231 sold.

Citigroup first reported a position in RUBY in Q3 2018 and held it in 17 quarters. The position peaked at $4.54M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Citigroup reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 1,342 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $231.
  • Citigroup first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 17 quarters.
  • Citigroup's Rubius Therapeutics, Inc position peaked at $4.54M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.